“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, August 02, 2017Pharma Major Lupin Limited reported its financial performance for the first quarter ending June 30th, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Financial & Performance Highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited, said “Our Q1, FY2018 results have been below our own expectations on count of higher than anticipated price erosion in select products like Glumetza, disruption on count of GST implementation in India and appreciation in the rupee. Our focus remains on building our complex generic pipeline, operational excellence, regulatory compliance and building a differentiated specialty business.”
Consolidated Unaudited financial Results – Quarter I, FY2018
Amount in Rs. m.
 The Company made a provision for liability towards its Australian subsidiary amounting to Rs. 1,559 m., in respect of compensation for patent litigation towards its Isabelle generic launch in Australia.
Income Statement highlights – Q1 FY2018
Balance Sheet highlights
Lupin’s North America sales for Q1 FY2018 were Rs. 16,018 m. compared sales of Rs. 19,007 m. during Q4 FY2017 and Rs. 21,886 m. during Q1 FY2017; accounting for 42% of Lupin’s global sales.
Lupin’s India formulation sales grew by 6.1% to Rs. 9,324 m. during Q1 FY2018 as compared to Q4 FY2017 and decreased by 1.8% compared to Q1 FY2017; accounting for 25% of Lupin’s global sales.
Lupin’s APAC sales were at Rs. 5,989 m. during Q1 FY2018 compared to sales of Rs. 6,118 m. during Q4 FY2017 and Rs. 5,416 m. during Q1 FY2017; accounting for 16% of Lupin’s global sales.
Lupin’s Japan sales increased by 8.1% to JPY 8,585 m. during Q1 FY2018 compared to JPY 7,945 m. during Q4 FY2017 and 25.0% compared to JPY 6,868 m. in Q1 FY2017.
Lupin’s Philippines sales were PHP 350 m. during Q1 FY2018 compared to PHP 615 m. during Q4 FY2017 and PHP 508 m. during Q1 FY2017.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales were Rs. 2,259 m for Q1 FY2018 compared to sales of Rs. 3,012 m. during Q4 FY2017 and Rs. 2,194 m. during Q1 FY2017; accounting for 6% of Lupin’s global sales.
Lupin’s South Africa sales were ZAR 209 m. during Q1 FY2018 compared to ZAR 325 m. during Q4 FY2017 and ZAR 205 m. during Q1 FY2017. Lupin remains the 4th largest generic player in the South African market.
Lupin’s Germany sales were Euro 6.7 m. during Q1 FY2018 compared to Euro 6.5 m. during Q4 FY2017 and Euro 6.4 m. during Q1 FY2017.
Latin America (LATAM)
Lupin’s LATAM sales were Rs. 1,269 m. during Q1 FY2018 compared to Rs. 1,269 m. during Q4 FY2017 and Rs. 1,089 m. during Q1 FY2017; accounting for 3% of Lupin’s global sales.
Lupin’s Brazil sales increased by 3.0% to BRL 36 m. during Q1 FY2018 compared to BRL 35 m. during Q4 FY2017 and 17.1% compared to BRL 31 m. during Q1 FY2017.
Lupin’s Mexico sales increased by 1.0% to MXN 149 m. during Q1 FY2018 compared to MXN 148 m. during Q4 FY2017 and 13.2% compared to MXN 132 m. during Q1 FY2017.
Global API sales were Rs. 2,793 m. during Q1 FY2018 compared to Rs. 2,815 m. during Q4 FY2017 and Rs. 2,966 m. during Q1 FY2017; accounting for 7% of Lupin’s global sales.
Research and Development
Revenue Expenditure on R&D during Q1 FY2018 amounted to Rs. 4,999 m., 13.1% of sales as against Rs. 6,709 m., 16.1% of sales during Q4 FY2017 and Rs. 4,994 m., 11.5% of sales during Q1 FY2017.
Lupin filed 1 ANDA and received 3 approvals from the US FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 368 as of June 30th, 2017, with the company having received 217 approvals to date. The Company now has 45 First-to-Files (FTF) filings including 23 exclusive FTF opportunities. Cumulative DMF filings stands at 187 as of June 30th, 2017.
The Company received approval for 3 MAA from the European authority during the quarter. Cumulative filings with European authorities now stands at 61 with the company having received 57 approvals to date.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).
For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information.
You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate communications
Ph: +91-22 6640 2531 / 9811665000
Head – Investor Relations and M&A
Ph: +91-22 6640 2137
Safe Harbor Statement